Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial

Tumor shrinkage was observed in 3 out of 4 patients; 1 out of 4 experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory...

Related Keywords

China ,Australia ,New Zealand ,Japan ,United States ,Ilya Rachman ,Alex Lobo ,Immix Biopharma Inc ,Nasdaq ,Nexcella Inc ,Company Contact ,Exchange Commission ,Escalation Proceeding ,Chief Executive Officer ,Immix Biopharma ,Tissue Specific Therapeutics ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Risk Factor ,Annual Report ,Markets ,